Aerie  
治疗青光眼药物

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Aerie's lead product candidate, AR-13324, is the first of a new dual-action drug class that was discovered by Aerie scientists. AR-13324 is a once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. Aerie's product candidate PG324 is a fixed combination of dual-action AR-13324 with latanoprost formulated in a single eye drop and is designed to lower intraocular pressure by reducing fluid inflow while also opening both of the eye's fluid drains.

Aerie is located in Bedminster, New Jersey, Research Triangle Park, North Carolina, and Newport Beach, California.